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Abstract 
 
We have previously reported that Morinda citrifolia (noni) puree modulates neonatal calves developmental maturation 
of the innate and adaptive immune system.  In this study, the effect of noni puree on respiratory and gastrointestinal (GI), 
health in preweaned dairy calves on a farm with endemic salmonellosis was examined. Two clinical trials were conducted 
whereby each trial evaluated one processing technique of noni puree. Trials 1 and 2 tested noni versions A and B, respectively.  
Puree analysis and trial methods were identical to each other, with the calf as the experimental unit. Calves were designated to 
1 of 3 treatment groups in each trial and received either: 0, 15 or 30 mL every 12 hr of noni supplement for the first 3 weeks of 
life. Health scores, weaning age, weight gain from admission to weaning, and weaned by 6 weeks, were used as clinical 
endpoints for statistical analysis. In trial 1, calves supplemented with 15 mL noni puree of version A every 12 hr had a higher 
probability of being weaned by 6 weeks of age than control calves (P = 0.04). In trial 2, calves receiving 30 mL of version B 
every 12 hr had a 54.5% reduction in total medical treatments by 42 days of age when compared to controls (P = 0.02). There 
was a trend in reduced respiratory (61%), and GI (52%) medical treatments per calf when compared to controls (P = 0.06 and 
0.08, respectively). There were no differences in weight gain or mortality for any treatment group in either trial. 
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Introduction 
 
The globally emergence of new and resistant pathogens in dairy herds in conjunction with the improper use of 
antibiotics is challenging the success of herd health management programs to maintain biosecurity and international economic 
trade.  This perspective is supported by The European Union’s ban of antibiotics and related drugs on livestock for the purpose 
of growth promotion (Commission Press Room, 2003) and the Food and Drug Administration and World Health Organization 
support of similar policies being be adopted by the United States (FDA, 2000; Ferber, 2003).  
The animals most at risk for contracting disease on modern dairy farms are neonatal calves as their immune system is 
developmentally immature and incapable of mounting an adequate defense against many infectious pathogens, such as 
Salmonellosis (Chase et al., 2008). While adequate colostrum intake and properly used antibiotics can provide much protection 
(Berge et al., 2005), increased antibiotic scrutiny and consumer demand for organic products has prompted investigations of 
ethnoveterinary practices for enhancing dairy production by improving calf health and well-being through disease prevention 
(Gakuya et al., 2011; Akerreta et al., 2010;Dilshad et al., 2010;Bonet and Valles, 2007).  Improving calf health through the 
validation of safe, effective and relatively inexpensive ethnoveterinary remedies to enhance preruminant dairy calf immunity 
has economic benefits for the producer as well as the broader dairy and beef industries by producing more cost efficient 
products that are more marketable (Matsabisa et al., 2012; Lans et al., 2007; Ahmadu et al., 2007; Blecha, 2001). 
While the neonatal calf is capable of mounting an immune response at birth, its response is best characterized as 
immune-naïve.  The role of diet and nutrition in maintaining a well-balanced immune system are well recognized and recent 
findings demonstrating immune modulation with bioactive food components and ingredients, such as pre- and probiotics, -
glucans and fungal immunomodulatory proteins, support the notion that natural products can potentially replace the use of 
prophylactic antibiotics in pre-ruminant animal health and well-being. The Morinda citrifolia (noni) fruit is a natural product 
with global equatorial distribution and established validated bioactive compounds that support its ethnoveterinary applications 
(Razafimandimbison et al., 2011; Kinghornet al., 2011; Deng et al., 2010a; West et al., 2010; Razafimandimbison et al., 2010; 
Pawlus and Kinghorn, 2007). 
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The noni fruit has a broad range of validated immune enhancing effects including: antibacterial, anti-inflammatory, anti-cancer 
and anti-oxidant activity (Nitteranon et al., 2011, Kusirisin et al., 2009; Akihisa et al., 2007; Yang et al., 2007, Pawlus et al., 
2005). The Iridoid and polysaccharide fractions of noni has been shown to induce the release of several immune mediators, 
many of which have beneficial stimulatory effects and may aid in the maturation of the neonatal immune system (Deng et al., 
2010b; Bui et al., 2006 ); Hirazumi and Furusawa, 1999).  
Previously, we examined the effects of feeding calves noni puree for the first 2 weeks of life on a parameter of innate 
immunity.  Bacterial killing was evaluated via an ex vivo whole blood bactericidal assay (Schäfer et al., 2008). Noni 
supplemented calves showed significantly more killing power at day 14 when compared to control calves.  Additionally, the 
added benefit of noni increased over time from day 3 to 14. 
To determine if the immune enhancing effect of noni was broad based, including both innate and adaptive responses, 
we investigated the effects of feeding calves noni puree for the first 2 weeks of life on T cell activation. We evaluated mitogen-
induced T cell activation via expression of interleukin-2 receptor (IL-2r, CD25) (Brooks et al., 2009). Results showed noni 
puree-fed calves had increased increase in CD25 expression on CD4+ and CD8+ T cells on day 3 of the study or approximately 
4 to 5 days postpartum, as well as an up-regulatory effect over time, (0 to 14 days), for CD8+ T cells. 
Taken together, in vitro and in vivo studies demonstrate immune modulating function of noni fruit puree in calves.  As 
such, we postulated that these enhanced immune responses may translate into increased health and well-being for newborn 
Holstein dairy calves raised in a gram negative bacterial challenged environment on a commercial operation, thus validating 
it’s ethoveterinary application in a clinical study. To address this, two clinical trials were performed, each to analyze one 
version of a noni fruit puree supplement for calves (Morinda Agricultural Products, Inc., Provo UT, USA). A low and high 
dosage of each version was tested to investigate potential dose-effects. The trials were performed on a commercial heifer 
rearing facility with a confirmed history of endemic salmonellosis. The effects on weaning age, weight gain, incidence of 
disease events and mortality in neonatal calves were analyzed through weaning. 
 
 
Materials and methods 
Noni puree products 
 
Each clinical trial evaluated either version A (trial 1) or B (trial 2). Differences between version A and B were the 
result of ingredient processing changes related to emulsion quality of the solution. There were no differences between version 
A and B in nutritional content or guaranteed analysis (Table 1). Methods used for product analysis follow the Association of 
Analytical Communities International (AOAC) and/or United States Pharmacopeia (USP) guidelines: pulp by centrifugation 
and gravimetric analysis; mineral content by ICP analysis against standards of known concentration; fat by acid hydrolysis 
followed by extraction with hexane; fat-soluble vitamins by saponification, extraction and reverse-phase HPLC with standards 
of known concentration; water-soluble vitamins by extraction and reverse-phase HPLC with standards of known concentration; 
moisture by microwave oven; fiber by standard method using enzymatic treatment and pH control; brix by refractometer; ash 
by gravimetric analysis. Protein content was determined by Standard Kjeldahl method (Sapan et al., 1999), which is used for 
the validation of analytical processes for the determination of protein concentration. The energy density found in a 15 mL 
aliquot of either version is minimal (10 calories or less). The product was stored at room temperature until use and added to 
small batches of freshly prepared milk replacer, which were consumed within 15 min of preparation. 
 
Animals 
 
The trials and procedures were reviewed and approved by the Institutional Animal Care and Use Committee of the 
University of Wisconsin-Madison.  The trials were conducted on a commercial calf-raising farm in Central Wisconsin. 
Microbiologic testing (UW-School of Veterinary Medicine, Clinical Microbiology) of fecal and post mortem derived samples 
from at least one pre-weaned calf from each of the calf barns prior to, and during, the trials confirmed the presence of multiple 
drug resistant Salmonella dublin and Salmonella newport on this farm. At capacity, the farm can accommodate approximately 
280 preweaned calves, 60 weaning calves, and 220 weaned calves. Historically, the average heifer calf on this farm began 
weaning on day 49, when they were moved into group housing and no longer offered milk replacer. For the purposes of this 
study calves received 2.25 L of milk replacer that had been reconstituted according to the manufacturer’s instructions (Table 2, 
Akey Inc., Lewisburg OH, USA) twice a day in a bucket until weaning.  Calf starter (Table 2, Vita Plus, Madison WI, USA), 
was offered daily at the farm from first arrival until weaning, which was defined by calves consuming 0.9 kg (2 lb) per day for 
3 consecutive days in addition to their milk replacer. Between feedings, calves had access to 2 L of fresh water or BlueLite 
electrolytes (Table 3, TechMix, Inc., Stewart MN, USA), which alternated every other day. 
Starter refusals were discarded and replaced with 0.9 kg starter once daily for each calf. Trial 1 enrolled 112 calves 
and 114 calves were enrolled in trial 2. All calves were Holstein heifers and were followed to weaning. Calves arrived from a 
4,000 cow commercial dairy in North-Central Wisconsin where they had been housed individually on straw and transported 
within 3 days of birth. Travel time to the trial site was approximately 2 h. At the trial farm, calf pens, approximately 1.2 m × 2 
m in size, were located in 4 separate barns. The pens were separated by metal fencing, aligned in 2 rows and bedded with 
straw. Fresh kiln dried shavings were added to pens weekly; no bedding was removed until the calf was moved into group 
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housing for weaning. Fence spacing did allow for calves to come in direct contact with their adjoining neighbors, which often 
occurred after feeding.  
 
Treatment Allocation 
 
Upon arrival at the trial farm, calves were weighed immediately after being unloaded and randomly assigned to 1 of 
the 3 treatment groups.  Final weights were measured the day the calves were moved to group housing. Both weights were 
taken between the morning and evening feedings. Randomization of treatment assignment order for a total population of 250 
calves, to include all enrollees of trials 1 and 2, was generated with R (R Foundation for Statistical Computing, ver.2.4.1. 
Vienna, Austria). How many calves were in each group? For trials 1 and 2, Group 1 served as a control (n=34 and 39), whereas 
groups 2 (n=35 and 38), and 3 (n=38 and 32) received 15 mL every 12 hr or 30 mL every 12 h, respectively, of a noni fruit 
puree-based supplement in their milk replacer for 21 d. Those responsible for feeding used a color-coding system to 
differentiate the noni treatment groups. Technicians overseeing the trials were blinded to treatments, as they were not present 
during feedings. Calves were assigned to barns by completely filling an available barn before moving to the next.  The 
restricted randomization of the treatments upon admission insured that each barn had approximately the same proportion of 
calves assigned to each treatment group. 
 
Inclusion Criteria 
 
Blood samples were taken from each animal in 5 mL monoject tubes (Tyco Healthcare Group LP, Mansfield MA, 
USA) for total serum protein and IgG analysis upon arrival at the trial farm to determine if the calf had received adequate 
passive transfer through the ingestion of colostrum. Blood samples were allowed to clot for 18 hr at room temperature before 
the serum was removed and stored at 4 C. Serum samples were analyzed by the University of Wisconsin, School of 
Veterinary Medicine’s clinical pathology laboratory. Calves with IgG levels  1000 mg/dL (Weaver et al., 2000; Schäfer et al., 
2008), and total protein levels  5.0 g/dL were considered to have adequate passive transfer, and calves with lower levels were 
classified as having failure of passive transfer and subsequently removed from the trial. Calves were also removed from the 
trial if their starting weight did not fall between 32 and 54.5 kg, or if they died within 48 hr of arrival at the calf-raising farm. 
A total of 5 calves were removed from each trial for failing to meet these criteria. 
 
Experimental Procedure 
 
Calf health was evaluated through daily physical evaluations, which were recorded as health scores as previously 
described (Schäfer et al., 2008). Every animal received daily physical examinations, including observations on rectal 
temperature, ease of cough induction by manual compression of the trachea, fecal consistency, nasal discharge and presence 
and severity of ocular or otic abnormalities, which were aligned with specific respiratory, gastrointestinal (GI), and pyrexic 
disease events and subsequent predetermined medical treatment regimens. Technicians blinded to noni treatment groups and 
recorded daily as calf health scores, which dictated whether the calf required medical treatment, performed calf health 
evaluations (Table 4). Calves receiving a combined respiratory score (temperature, cough, nasal discharge and eyes or ears)  
5, a fecal score  2 or a temperature  39.4C were classified as having an incidence of disease and subsequently treated by 
farm personnel according to the established farm protocol (Table 5). Medical treatments were divided into respiratory disease 
related antibiotics, gastrointestinal disease related antibiotics, non-steroidal fever reducers and electrolytes. Calves that 
experienced a second respiratory disease event after receiving the first full antibiotic treatment, received the second respiratory 
antibiotic. Likewise, calves that experienced a third or subsequent respiratory disease incidence, received the third respiratory 
antibiotic. 
 
Statistical Analysis 
 
All statistical analysis was performed in SAS (SAS Institute, Cary NC, USA).  Each trial was analyzed separately, 
with the calf as the experimental unit.  Health scores (fecal, respiratory, and total), weaning age, weight gain from admission to 
weaning, and whether the calf was weaned by 6 weeks, were used as clinical endpoints for statistical analysis. All models were 
corrected for body weight at admission (a continuous variable) and the barn a calf was housed in (a categorical variable). 
Dosage of version A and B for calves (0, 15 or 30 mL every 12 h) was treated as a 3-level factor rather than as the actual 
numerical dose because preliminary graphs of the data indicated a possible non-linear relationship between dose and the 
endpoints of interest. Health scores were analyzed with Poisson regression models using Proc GENMOD, using the likelihood 
ratio test to evaluate the overall effect of each variable. Ages at weaning and weight gain were analyzed with linear models in 
Proc MIXED, using F-tests to evaluate overall effects. Residuals for the linear models were checked and verified to meet the 
necessary assumptions of normality and constant variance across treatment groups. Whether the calf was weaned by 6 weeks 
or not was analyzed with a logistic regression model using Proc GENMOD, again using the likelihood ratio test to evaluate 
overall effects and additionally using odds ratios with Wald P-values to look at pairwise comparisons of the doses after a 
significant likelihood ratio test. Treatment effects were considered significant at P ≤ 0.05 and trends were identified at P < 
0.10. 
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Results 
 
Results of trial 1 revealed that supplementing calves with version A had an effect on the probability of being weaned 
by 6 weeks of age compared to control (Table 6).  Calves receiving 15 mL noni puree every 12 hr of version A (low dose) had 
a higher probability of being weaned by 6 weeks of age than non-supplemented (control) calves (odds ratio 2.97; P = 0.04). In 
trial 2, calves receiving 30 mL every 12 hr of version B had a 54.5 % (P = 0.02), reduction in total respiratory and GI health 
scores when compared to controls (31 vs. 68, respectively).  Individually, there was a trend in reduced respiratory (P = 0.06), 
and GI (P = 0.08), health scores for the same group of calves when compared to controls (7 vs. 18, 61% and 24 vs. 50, 52%), 
respectively. There was no difference in weight gain and average daily gain for any treatment group in either trial. 
 
 
Table 1:  Analysis and ingredients of Noni fruit puree for trial 1 (version A), and trial 2 (version B). 
Parameter Version Aa Version Ba 
Protein, % 2.55 2.65 
Fat, % 2.67 1.47 
Ash, % 0.54 0.54 
Moisture, % 86.57 82.94 
Insoluble Fiber, % 0.67 1.52 
Soluble Fiber, % 1.67 1.95 
Viscosity, centipoise 3560 4180 
pH 4.03 4.01 
aGuaranteed Analysis: Crude Protein (not less than) 2.0%, Crude Fat (not less than) 0.5%, Crude Fiber (not more than) 3.0%, 
Vitamin E (not less than) 400 IU/30 mL. Ingredients: Morinda citrifolia (noni) fruit, water, dl-alpha-tocopheryl acetate 
(vitamin E), soy lecithin, xanthan gum, flaxseed oil, vegetable oil, mixed tocopherols, and rosemary extract. 
 
 
 
Table 2:  Milk replacer and starter information as provided from Manufacturer labels. 
Milk Replacera Active Drug Ingredients 
Oxytetracycline: 0.134 g/kg 
Neomycin Sulfate: 0.382 g/kg 
Guaranteed Analysis: 
Crude Protein ……Min. 26.0% 
Crude Fat ………..Min. 17.0% 
Crude Fiber ……...Max. 0.1% 
Calcium (Ca).........Min. 1.0%; Max. 1.0% 
Phosphorous (P)......Min. 0.6% 
Vitamin A ................Min. 51,480 IU/kg 
Vitamin D3 ..............Min. 11,000 IU/kg 
Vitamin E.................Min. 220 IU/kg 
Calf Starterb Guaranteed Analysis: 
Crude Protein …….Min. 17.5% 
Crude Fat …………Min. 5.0% 
Crude Fiber ………Max. 0.8% 
Calcium (Ca).........Min. 1.3%; Max. 1.0% 
Phosphorous (P).....Min. 0.5% 
Salt......................Min. 0.4%; Max. 0.7% 
Selenium …………..0.6 ppm 
Vitamin A ................Min. 51,480 IU/kg 
Vitamin D3 ..............Min. 11,000 IU/kg 
Vitamin E .................Min. 220 IU/kg 
aAkey Inc., Lewisburg OH, USA 
bVita Plus, Madison WI, USA 
 
 
 
 
Table 3:  Electrolyte replacement information as provided from Manufacturer labels. 
Electrolytesc Guaranteed Analysis: 
Ingredients: Dextrose, Sucrose, Lactose, Fructose, Citric Acid, Dipotassium Phosphate, Potassium Chloride, 
Sodium Chloride, Calcium Lactate, Magnesium Gluconate, Sodium Bicarbonate, Glycine, l-Lysine Monohydro-
chloride, Zinc Methionine Complex, Vitamin A Acetate, d-Activated Animal Sterol (source of Vitamin D3), dl-
Alpha Tocopheryl Acetate (source of Vitamin E activity), Choline Bitartrate, Niacin Supplement, Ascorbic Acid, 
d-Calcium Pantothenate, Riboflavin Supplement, Pyrioxine Hydrochloride, Thiamine Mononitrate, Folic Acid, d-
Biotin, Vitamin B12 Supplement, Artificial Flavors, FD&C Certified Color Added. 
cTechMix, Inc., Stewart MN, USA 
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            Table 4: Calf Health Scoring Criteria 
Score Temperature Cough Nasal Discharge Eyes or ears Fecal Score 
0 37.8-38.3 °C None Normal serous 
discharge 
Normal Normal 
1 38.3-38.8 °C Induce single 
cough 
Small amount of 
unilateral, cloudy 
discharge 
Small amount of 
ocular discharge 
Semi-formed, 
pasty 
2 38.9-39.4 °C Induced repeated 
cough or 
occasional 
spontaneous 
cough 
Bilateral, cloudy or 
excessive mucus 
discharge 
Moderate amount of 
discharge from both 
eyes or slight ear 
drop 
Loose but 
enough 
consistency to 
stay on 
bedding 
3 > 39.4 °C Repeated 
spontaneous 
coughing 
Copious, bilateral, 
mucopurulent nasal 
discharge 
Head tilt or both ears 
dropped 
Watery, sifts 
through 
bedding 
 
Table 5:  Established farm protocol. Calf health scores derived through from physical evaluations dictated calf medical 
treatment regimens. 
Health Score Treatment Dose Tx 
#a 
Route 
Fecal = 2 Electrolytesb 2 L 1 oral 
Fecal = 3 Electrolytes  2 L 2 oral 
Fecal = 2 + blood Electrolytes  
Gentamicinc 
2 L 
2 cc 
1 
1 
oral 
oral 
Fecal = 3 + blood Electrolytes  
Gentamicin  
2 L 
2 cc 
2 
1 
oral 
oral 
2 cc 1 s.c. 
2 cc 1 i.m. 
Total respiratory score of ≥ 5  1st Ceftiofurd 
2ndTulathromycine 
3rd Trimethoprim Sulfaf 
960 mg 6 oral 
Temperature ≥ 39.4°C Flunixin meglumineg 2 cc 1 i.m. 
i.m., Intramuscular; s.c. Subcutaneous;  aNumber of treatments (Tx) given for the disease incidence. 
bTechMix, Inc., Stewart MN, USA; c, gIntervet/Schering-Plough Animal Health, The Netherlands 
d,ePfizer Inc., New York NY, USA; fMutual Pharmaceutical Co. Inc., Philadelphia PA, USA 
 
Table 6: Summary of calf production data for trail 1 (version A) and trial 2 (version B). 
 Trial 1 with Version A Trial 2 with Version B 
 Control Low dose High dose Control Low dose High dose 
Calves (n) 34 35 38 39 38 32 
Initial age (d) 1.97 ± 0.20* 
2.43 ± 
0.20 
1.95 ± 
0.18 
2.10 ± 
0.21 
2.18 ± 
0.21 
2.06 ± 
0.20 
Weaning age (days) 43.15 ± 0.86 
40.91 ± 
0.67 
42.61 ± 
0.69 
39.90 ± 
0.77 
39.21 ± 
0.77 
38.69 ± 
0.67 
Initial BW 40.6 ± 0.85 41.05 ± 0.64 
40.71 ± 
0.94 
40.51 ± 
0.73 
41.0 ± 
0.66 
41.32 ± 
0.71 
Weaning BW 80.5 ± 1.54 78.16 ± 1.35 
78.45 ± 
1.32 
79.74 ± 
1.12 
80.85 ± 
1.11 
81.07 ± 
1.41 
ADG (kg/d) 0.89 ± 0.03 0.91 ± 0.02 
0.89 ± 
0.02 
0.98 ± 
0.03 
1.03 ± 
0.03 
1.03 ± 
0.03 
Weaned by 6 weeks 
of age (%) 47.10 74.29† 47.40 84.62 81.58 87.50 
Total respiratory 36 27 39 18 19 7 
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health score 
Total GI health score 35 32 47 50 36 24 
Total respiratory & 
GI health scores 71 59 86 68 55 31†
 
*, mean ± sem; BW, Body weight (kg); ADG, Average daily gain; Tx, Treatments; †, P< 0.05. 
Discussion 
 
Many of the statistics and conclusions in our study were principally based upon variables that were measured at 
weaning. We intentionally tried to mimic what is common practice on dairy farms, that is to base weaning on starter intake; 
such that calves were weaned when they had consumed 0.9 kg of starter for 3 consecutive days as confirmed by farm 
personnel. We were anxious not to intrude on the daily workings of the farm, and also to mimic what is a common place 
practice for heifer raisers nationally when investigating the impact of a product on weaning. It is highly relevant to point out 
that both the farm personnel and the technicians were blinded as to treatment groups and as such their quantification of grain 
intake and therefore weaning date were independent and unbiased with respect to supplementation with noni puree.  
Two clinical trials were performed to analyze the effect of a noni fruit puree-based liquid supplement for calves on a 
commercial heifer rearing facility with a confirmed history of endemic Salmonella dublin and Salmonella newport infection. 
The results of these trials demonstrated that calves receiving noni puree had a reduction in total medical scores (treatments), 
required relative to controls. 
Infection with multiple drug resistant enteric pathogens is an increasing challenge to the dairy industry, and often 
conventional veterinary therapeutic approaches are thwarted by their emergence. Our previous work has demonstrated 
improved bactericidal activity against gram negative organisms (Schäfer et al., 2008) and although our trials made no attempt 
to compare Salmonella infection rates or Salmonella-associated morbidity in the controls or treated calves, the increasing 
prevalence of resistant gram-negative enteric pathogens on heifer rearing facilities in the US perhaps argues well for the use of 
noni puree as an ethnoveterinary application to a commercial calf-raising setting. 
While it is tempting to attribute our observed results of earlier weaning and decreased disease incidences with noni 
puree supplementation, there are other potential influencers.  The noni puree contains Vitamin E, which is a recognized 
immunomodulator that promotes a T helper1 cell responses (Maggini et al., 2007; Webb and Villamor 2007;Samanta et al., 
2006). While the control calves were also supplemented with Vitamin E, which was present in the milk replacer and calf 
starter, it is possible that the net effect of the noni puree group induced a more profound immune response. However, two 
previous studies demonstrated enhanced phagocytosis of E. coli (Schäfer et al., 2008), and increased activation of CD4+ and 
CD8+ T cells (Brooks et al., 2009), in calves supplemented with noni puree without any additional ingredients. 
The animals most at risk for contracting infectious disease on modern dairy farms are neonatal calves as their immune 
system is developmentally immature and incapable of mounting an adequate defense against many infectious pathogens. 
Although adequate colostrum intake and properly used antibiotics can provide much protection (Berge et al., 2005), increased 
antibiotic scrutiny and consumer demand for organic products has prompted investigations of natural immunomodulators for 
enhancing calf health and production.  Improving calf health through the development and validation of a safe and effective 
immunomodulator for pre-weaned dairy calves has potential economic benefits for the producer as well as a broader global 
benefit to dairy and beef industries by reducing the broad based use of antimicrobials. 
 
Conclusion 
 
The results of these trials validate the ethnoveterinary application of noni fruit puree. They demonstrate that a natural, 
plant-based product is available to enhance immunity of neonatal calves and potentially long term health, provide an 
alternative to antibiotic use in calves and enable producers to raise healthier animals that require less time and treatment in the 
preweaning period. Further studies are warranted to identify bioactive components in noni puree responsible for modulating 
immune function. Other Rubiaceae family species indigenous to Africa may be investigated for ethnoveterinary applications. 
 
 
Acknowledgements 
 
 The authors thank Ken Leu and Judy Steinke for being wonderful hosts to the trials and providing exceptional 
oversight of animal health and well-being.  Conflict of Interest: This project was funded in part by Morinda Agriculture. 
 
 
References 
 
1. Ahmadu, A.A., Zezi, AU., Yaro, AH (2007). Anti-diarrheal activity of the leave extracts of Danielliaoliveri hutch and 
dalz (fabaceae) and ficus sycomorus miq (moraceae). Afr. J. Trad. Complement. Altern. Med. 4:524-528. 
Brooks et al., Afr J Tradit Complement Altern Med. (2013) 10(1):1-8 
http://dx.doi.org/10.4314/ajtcam.v10i1.1 
 
 
7
2. Akerreta, S., Calvo, MI., Cavero, RY (2010). Ethnoveterinary knowledge in Navarra (Iberian Peninsula). J. 
Ethnopharm. 130:369-378. 
3. Akihisa, T., Matsumoto, K., Tokuda, H., Yasukawa, K., Seino, K., Nakamoto, K., Kuninaga, H., Suzuki, T., Kimura, Y 
(2007). Anti-inflammatory and potential cancer chemopreventative constituents of the fruits of Morinda citrifolia 
(noni). J. Nat. Prod. 70:754-757. 
4. Berge, A.C.B., Lindeque, P., Moore, D.A., Sischo, WM (2005). A clinical trial evaluating prophylactic and therapeutic 
antibiotic use on health and performance of preweaned calves. J. Dairy Sci. 88: 2166-2177. 
5. Blecha, F (2001). Immunomodulators for prevention and treatment of infectious diseases in food-producing animals. 
Vet. Clin. North Am. Food Anim. Pract. 17: 621-633. 
6. Bonet, M.A., Valles, J (2007). Ethnobotany of Montsenyh biosphere reserve (Catalonia, Iberian Peninsula): Plants used 
in veterinary medicine. J. Ethnopharm. 110:130-147. 
7. Brooks, V.J., Peek, S.F., Godbee, R.G., Schultz, R.D., Suresh, M., Darien, B.J (2009). Effects of Morinda citrifolia 
(Noni) on CD4+ and CD8+ T-cell activation in neonatal calves. The Professional Animal Scientist. 25: 262–265. 
8. Bui, A.K.T., Bacic, A., Pettolino, F (2006). Polysaccharide composition of the fruit juice of Morinda citrifolia (Noni). 
Phytochemistry 67: 1271–1275.   
9. Chase, C.C.L., Hurley, D.J., Reber, AJ (2008). Neonatal Immune Development in the Calf and Its Impact on Vaccine 
Response. Vet. Clin. Food Anim. 24: 87-104. 
10. Commission Press Room (2003). Council and Parliament prohibit antibiotics as growth promoters: Commissioner 
Byrne welcomes the adoption of regulation on feed additives. Commission Press Room IP/03/1058. European 
Commission, Brussels, Belgium. 
11. Deng, S., West, B.J., Jensen, CJ (2010a). A quantitative comparison of phytochemical components in global noni fruits 
and their commercial products. Food Chem. 122:267-270. 
12. Deng, S., West, B.J., Palu, A.K., Jensen, CJ (2010b). Determination and comparative analysis of major iridoids in 
different parts and cultivation sources of Morinda citrifolia. Phytochem. Anal. 22:26-30. 
13. Dilshad, S.M.R., Rehman, N.U., Ahmad, N., Iqbal, A (2010). Documentation of ethnoveterinary practices for mastitis in 
dairy animals in Pakistan. Pak. Vet. J. 30:167-171. 
14. Dusty M. Weaver, D.M., Tyler, J.W., VanMetre, D.C., Hostetler, D.E., Barrington, G.M (2000). Passive transfer of 
colostral immunoglobulins in calves. J. Vet. Intern. Med. 14: 569–577. 
15. Ferber, D (2003). Antibiotic resistance. WHO advises kicking the livestock antibiotic habit. Science 301:1027. 
16. Food and Drug Administration, Center for Veterinary Medicine (2000). HHS response to house report 106-157- 
agriculture, rural development, Appropriations Bill:  Human-Use Antibiotics in Livestock Production. 
http://www.fda.gov/cvm/HRESP106_157.htm 
17. Gakuya, D.W., Mulei, C.M., Wekesa, SB (2011). Use of ethnoveterinary remedies in the management of foot and 
mouth disease lesions in a dairy herd. Afr. J. Tradit. Complement. Altern. Med. 8:165-169. 
18. Hirazumi, A., Furusawa, E (1999). An immunomodulatory polysaccharide-rich substance from the fruit juice of 
Morinda citrifolia (Noni) with antitumor activity. Phytother. Res. 13: 380-387. 
19. Kinghorn, A.D., Chai, H., Ki Sung, C., Keller, WJ (2011). The classical drug discovery approach to defining bioactive 
constituents of botanicals. Fitoterapia. 82:71-79. 
20. Kusirisin W., Srichairatanakoo S., Lerttrakarnnon P., Lailerd N., Suttajit M., Jaikang C., Chaiyasut C (2009). 
Antioxidative activity, polyphenolic content and anti-glycation effect of some Thai medicinal plants traditionally used 
in diabetic patients. Medicinal Chem., 5: 139-147.  
21. Lans, C., Turner, N., Khan T., Brauer, G., Boepple, W (2007). Ethnoveterinary medicines used for ruminants in British 
Columbia, Canada. J. Ethnobiol. Ethnomed. 3:11. 
22. Maggini, S., Wintergerst, E.S., Beveridge,S., Hornig, DH (2007). Selected vitamins and trace elements support immune 
function by strengthening epithelial barriers and cellular and humoral immune responses. Br. J. Nutr. 98: S29-S35. 
23. Matsabisa, M.G., Sekhoacha, M.P., Ibrahim, O., Moodley, P., Faber, M (2012). Nutritional conent and a phase-1 safety 
clinical trial of a herbal-nutritional supplement (immunity) with putative immune-modulating properties. Afr. J. Tradit. 
Complement. Altern. Med. 9:19-23. 
24. Nitteranon, V., Zhang G., Darien B.J., Parkin K (2011). Isolation and synergism of in vitro anti-inflammatory and 
quinonereductase (QR) inducing agents from the fruits of Morinda citrifolia (noni). Food Research International 44: 
2271–2277.  
25. Pawlus, A.D., Su, B., Keller, W.J., Kinghorn, AD (2005). An anthraquinone with potent quinonereductase-inducing 
activity and other constituents of the fruits of Morinda citrifolia (noni). J. Nat. Prod. 68:1720-1722.  
26. Pawlus, A.D., Kinghorn, AD (2007). Review of the ethnobotany, chemistry, biological activity and safety of the 
botanical dietary supplement Morinda citrifolia (noni). J Pharmacy & Pharmacology 59: 1587-1609 
27. Razafimandimbison, S.G., McDowell, T.D., Halford, D.A., Bremer, B (2010). Origin of the pantropical and 
nutriceutical Morinda citrifolia L. (Rubiaceae): comments on its distribution range and circumscription. J. Biogeogr. 
37:520-529. 
28. Razafimandimbison, S.G., Halford, D.A., McDowell, T.D., Bremer, B (2011). Proposal to conserve the name Morinda 
citrifolia (Rubiaceae) with a conserved type. Taxon. 60:607. 
Brooks et al., Afr J Tradit Complement Altern Med. (2013) 10(1):1-8 
http://dx.doi.org/10.4314/ajtcam.v10i1.1 
 
 
8
29. Samanta, A.K.,Dass, R.S., Rawat, M., Mishra, S.C., Mehra, U.R (2006). Effect of dietary vitamin E supplementation on 
serum a-Tocopherol and immune status of crossbred calves. Asian-Aust. J. Anim. Sci. 19:500-506. 
30. Sapan, C.V., Lundblad, R.L., Price, N.C (1999). Colorimetric protein assay techniques. Biotechnol. Appl. Biochem. 29: 
99-108; 
31. Schäfer, M., Sharp, P., Brooks,V.J., Xu, J., Cai, J., Keuler, N.S., Peek, S.F., Godbee, R.G., Schultz, R.D., Darien, B.J 
(2008). Enhanced bactericidal activity against Escherichia coli in calves fed Morinda citrifolia (noni) puree. J. Vet. 
Intern. Med. 22: 499-502. 
32. Webb, A.L., Villamor, E (2007). Update: Effects of antioxidant and non-antioxidant vitamin supplementation on 
immune function. Nutr. Rev. 65: 181-217.  
33. West, B.J., Dent, S., Jensen, C.J (2010). Nutrient and phytochemical analyses of processed noni puree. Food. Res. Int. 
44:2295-2301. 
34. Yang, J., Paulino, R., Janke-Stedronsky, S., Abawi, F (2007). Free-radical-scavenging activity and total phenols of noni 
(Morinda citrifolia L.) juice and powder in processing and storage.  Food Chem. 102: 302-308.  
 
